Step Pharma
Erik has over twenty years’ experience in the pharmaceutical and biotechnology industries. Previously, as a Senior Executive at Organon he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships, most recently the $600M alliance with Pfizer and raised more than €200M in equity and debt financing for biotechnology companies from seed through IPO. Erik is board member of Lava Therapeutics, Heatmatrix, Lead Pharma, Step Pharma and the Dutch biotechnology organization. Erik has an MSc in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK) both with distinction.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Step Pharma
Step Pharma is developing a novel class of oral nucleotide synthesis inhibitors specifically targeting cytidine triphosphate synthase 1 (CTPS1) to induce selective modulation of T and B cell populations.